

Partisanship, limits necessary in government undertakings, 2876

Patent Act amendment bill, 1992, Royal Assent process, government position, 2765

Patent amendment bill C-91, 1r, 2411; 2r, 2421-26; m to allocate time, 2426; on div, 2452-57; 2r, (con't) 2457-82, 2484-94, 2495-516, 2536, on div, 2536; ref to com, 2536; reported without amdt but with observations, 2597-600; 3r, 2623-40, 2652-56, 2656-64; m in amdt (Hébert), 2664-65; 3r, (con't), 2665-68, point of order, 2668-70; 2683-84; div on m in amdt (Hébert) deferred, 2685; m in amdt (Gigantès), 2685-88; m in amdt (Hébert) neg, 2703-04; 3r, (con't), 2705-06; div on m in amdt (Gigantès) deferred, 2706; m in amdt (Cools), 2706-09; div on m in amdt (Cools) deferred, 2709; 3r, (con't), 2709-10; m in amdt (Bosa), 2710; m to allocate time, 2713-14, 2732-33; m in amdt (Gigantès) neg on div, 2733-34; m in amdt (Cools) neg on div, 2734-35; m to allocate time, on div, 2735-37; m in amdt (Bosa) neg on div, 2737-38; 3r, (con't), 2738-58, on div, 2759-60; r.a., chap. 2, 1993, 2787

American drug prices, 2464

Bill C-22, 2422, 2458, 2459, 2460, 2625, 2666

Bill C-22 and free trade, 2478, 2489, 2490, 2491, 2492, 2493, 2494, 2497

Biomedical research, 2653

Canadian Drug Manufacturers Association, 2744

Closure, 2733, 2735, 2738

Companies' role, 2624

Competitiveness, 2684

Compulsory licensing, 2422, 2425, 2457, 2459, 2462, 2463, 2466, 2468, 2469, 2475, 2478, 2479, 2484, 2485, 2626, 2656, 2705, 2708, 2744, 2746, 2749

Cost increase, 2657

Cost of prescription drugs, 2658

Costs, 2628, 2633, 2661, 2669

Drug costs, 2624, 2629

Drug formulary, 2748

Drug prices, 2424, 2461, 2462, 2466, 2467, 2469, 2474, 2476, 2479, 2481, 2486, 2501, 2502, 2503, 2504, 2505, 2506, 2508, 2626, 2661, 2662, 2666, 2748, 2750, 2752, 2753

Dunkel report, 2652, 2656, 2667, 2687

European prices, 2753

Evergreening, 2709, 2710

Filibuster, 2732, 2733

Fine chemical companies, 2631

Foreign ownership, 2754

Funding for research and development, 2751

General Agreement on Tariffs and Trade, 2463, 2469, 2471, 2477, 2496, 2497, 2511, 2512, 2626, 2633, 2705

Generic companies, 2626, 2748

Generic drug manufacturers, 2631

Generic drugs, 2466, 2633, 2752

Generic firms, 2684

Generic industry, 2653

Generic sales, 2684

Guillotine, 2452, 2453

Health care, 2746

Health care costs, 2629, 2653, 2706

Inflation, 2666

Intellectual property rights, 2652

International agreements, 2624, 2625

Introductory price regulation system, European, 2634

Investment, 2624, 2625, 2667

Jobs, 2423, 2424, 2460, 2624, 2625, 2626, 2633, 2750

Liberal observations, 2624

Life of patents, 2709

Limiting debate, 2452

Lobbying, 2472, 2498, 2499, 2744

Market exclusivity, 2465, 2684

Medical research, 2659

Patent amendment bill C-91—Cont'd

Medicare, 2457, 2500, 2501, 2654

Multinational pharmaceutical companies, 2738

National Anti-Poverty Organization, 2629, 2634

Non-working of patents, 2709

North American Free Trade Agreement, 2463, 2464, 2465, 2469, 2471, 2652, 2705

Notice of Compliance, 2745

Parliamentary review, 2753

Patent protection, 2421, 2422, 2462, 2473, 2475, 2485, 2652, 2710, 2748

Patented Medicine Prices Review Board, 2421, 2423, 2458, 2459, 2461, 2465, 2466, 2467, 2474, 2475, 2502, 2625, 2627, 2630, 2631, 2656, 2707, 2748, 2750

Pharmaceutical industry, 2652, 2653

Pharmaceutical Manufacturers Association of Canada, 2744

Pharmaceutical sector, 2684

Poverty, 2654

Presentation of petitions, 2650, 2681, 2698, 2763, 2764

Provincial compensation, 2632, 2633

Provincial drug benefit programs, 2666

Provincial governments, 2756, 2758

Provincial health care, 2654, 2662

Provincial health plans, 2752

Question of privilege, 2600-10

Report of Banking, Trade and Commerce Committee, omission of minority observations, question of privilege, 2618

Research and development, 2423, 2425, 2458, 2459, 2464, 2466, 2467, 2475, 2476, 2479, 2486, 2487, 2488, 2501, 2509, 2625, 2626, 2627, 2632, 2633, 2663, 2666, 2667, 2748, 2749, 2750, 2751, 2753, 2755

Retroactivity, 2463, 2468, 2475, 2477, 2479, 2633, 2635, 2655, 2667, 2687, 2748

Rules, 2636, 2637, 2638, 2639

Scientific progress, 2753

Tax increases, 2495, 2496

Time allocation, 2452, 2453, 2454, 2455, 2456

Universal health care, 2465

Vaccines, 2746, 2747, 2757

Speakers: Senators

Austin, Jack, 2606, 2609

Barootes, Efstathios, 2597-600, 2602, 2608-09, 2656, 2669, 2757, 2758

Beaulieu, Mario, 2421-24, 2425, 2426, 2536, 2623, 2624-27

Bolduc, Roch, 2481

Bonnell, M. Lorne, 2500-03, 2654-56

Bosa, Peter, 2475-77, 2635, 2709-10

Cogger, Michel, 2515

Cools, Anne, 2497-500, 2601, 2607, 2609, 2706-09

Corbin, Eymard G., 2510-11, 2515, 2670

Davey, Keith, 2749

De Bané, Pierre, 2468, 2754-56, 2757-58

Di Nino, Consiglio, 2652-54, 2705-06

Fairbairn, Joyce, 2477-78, 2479-80, 2481

Frith, Royce, 2424-25, 2452-54, 2455, 2456, 2478, 2479, 2481, 2482, 2484-94, 2513, 2515, 2600-01, 2602-05, 2606, 2607, 2608, 2609, 2610, 2624, 2635, 2636, 2637, 2638, 2639, 2640, 2688, 2706, 2732-33, 2738-48

Gigantès, Philippe Deane, 2425, 2536, 2503, 2504-06, 2507, 2513, 2515, 2536, 2606, 2607, 2608, 2609-10, 2669, 2670, 2685-88, 2757

Grafstein, Jerahmiel, 2425, 2468-71

Hastings, Earl, 2710

Hays, Dan, 2495-97

Hébert, Jacques, 2513-14, 2661-64, 2706, 2709

Johnson, Janis, 2748-49

Kelleher, James, 2683-84

Kelly, William, 2665-68, 2704

Keon, Wilbert, 2465-67, 2468, 2481, 2752-54

Kirby, Michael, 2457-60, 2461-64, 2465, 2624, 2627-35

Lavoie-Roux, Thérèse, 2659, 2660-61